title: A report from the 29th Annual Congress of the European Association of Urology (April 11-15 - Stockholm, Sweden).
abstract: The annual congress of the European Association of Urology in Stockholm was packed with mixed poster/oral sessions wherein innovative clinical and preclinical research aimed at improving the care of patients with urinary tract diseases was reported and open for discussion. Not everything that was reported during the meeting can be captured in a single report, but the following text will guide readers through the most significant new findings directly related with pharmacotherapy for overactive bladder, urinary tract cancer and other common medical conditions that endanger the quality of life and life expectancy of many patients worldwide.
authors.affiliation: Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com.
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D013548:Sweden; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D053201:Urinary Bladder, Overactive / Q000188:drug therapy; D014565:Urogenital Neoplasms / Q000188:drug therapy*; D014570:Urologic Diseases / Q000188:drug therapy*
keywords: Benign prostatic hyperplasia; Genitourinary tract cancer; Overactive bladder; Urology